3 Topic Commentaries

Targeted therapy tested in dermatomyositis

• 

  Rohit Aggarwal, MD, MS

  Rheumatology

  •

  University of Pittsburgh Department of Medicine

  Dermatomyositis has long been one of the most challenging diseases to manage, often robbing patients of their mobility, independence, and quality of life,” noted Aggarwal. “The VALOR trial results signal a turning point. Brepocitinib has the potential to transform how we care for these patients, moving us away from broad immunosuppression and steroid dependence toward therapies that precisely target the immune pathways driving the disease.

  Source
• 

  J. Michelle Kahlenberg, MD, PhD

  Rheumatology

  •

  University of Michigan Medical School

  Together, this data provides a comprehensive cross-disease characterization of lesional and non-lesional skin in dermatomyositis and gives evidence on why JAK1 inhibition may offer therapeutic hope for dermatomyositis patients,” said Kahlenberg.

  Source
• 

  Julie Paik, MD

  Rheumatology

  •

  Johns Hopkins Medicine

  I thought a JAK inhibitor might be exactly what this person and many of my refractory DM patients needed,” she recalls.

  Source